AllCells is now a Discovery Life Sciences™ company. Together, we deliver a revolutionary set of scalable solutions to accelerate cell and gene therapy programs at every stage of development.
Cell and gene therapies are heralded as the future of precision medicine, but challenges in obtaining reliable, high quality cellular starting materials and defining appropriate process analytics threaten to slow progress. Discovery’s and AllCells’ combined capabilities present a scalable, end-to-end solution that provides unrivaled access to reliable human cellular starting materials with integrated analytic services.
30+ years of combined experience serving the CGT market with unrivaled speed, continuity and scale using optimized donor management infrastructures, extensive recallable donor pools, and industry-leading viability and purity standards.
Access to tens of thousands of well-characterized, highly engaged recallable donors from Discovery Donor Clinic and LeukoLab™ collection sites across the US and Europe to support projects at any scale.
Receive human cellular starting materials within 24 to 48 hours of placing an order, and make decisions faster with data from integrated analytic services.
RUO and GMP-grade fresh and cryopreserved normal and mobilized leukopaks to support early discovery to commercial manufacturing.
High quality products with industry-leading viability for optimal consistency and reproducibility.
Integrated Analytic Service
Cell isolation, cell culture, and immunophenotypic and functional profiling services adjacent to donor clinics to help define process analytics and inform decision-making.
Science at Your Service™
Ready access to scientific experts who help optimize projects with an innovative, collaborative, flexible and client-centric approach.
Frequently Asked Questions
Frequently Asked Questions
How can the acquisition of AllCells by Discovery Life Sciences accelerate my CGT projects?
Two industry leaders are better than one! The combination of our collective solutions means increased selection, speed, and scale with the same trusted commitment to flexibility, client service, and quality enabled by an expanded team of CGT experts. Speak to an expert today to initiate your CGT project.
What does the acquisition of AllCells by Discovery Life Sciences mean for my ongoing projects at Discovery and/or AllCells?
Your success is our number one priority. AllCells’ dedicated team and Discovery’s world-class expertise will continue to serve the biomedical research community with the same dedicated experts you have trusted for years. The flow of your projects and timelines will be unaffected by the acquisition.
How will this change my interaction with Discovery and/or AllCells?
We do not anticipate any changes to how you interact with Discovery and AllCells representatives, beyond having access to added expertise and capabilities.
What will happen with our existing contract(s) or master services agreement(s) with AllCells?
Our legal teams will work with clients to implement any needed updates in a timely fashion on a case-by-case basis with the mutual goal of causing no or minimal disruption to ongoing projects.
Where are your collection sites?
Our Research Use Only (“RUO”) and our Good Manufacturing Processes (“GMP”) collections are conducted in sites across the US including Alabama, California, Massachusetts, and Texas. Our Cell Biology Labs are often vertically integrated onsite in the same facilities, enabling real-time fresh processing or downstream manipulation as needed.
Are your apheresis donors recallable?
Yes, we have a pool of 10,000+ of healthy, reliable, recallable donors. Using more than 30 years of combined experience, we have carefully cultivated deep relationships with our donors and built a reliable supply chain optimized for speed and scale.